154
Participants
Start Date
September 28, 2023
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2027
lorigerlimab
Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4
docetaxel
Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
Prednisone
A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
Icahn School of Medicine at Mount Sinai, New York
University of Virginia Health System Cancer Center, Charlottesville
Orlando Health Cancer Institute, Orlando
United Medical Group, Miami
Nebraska Cancer Specialists, Grand Island
MD Anderson Cancer Center, Houston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Peter MacCallum Cancer Centre, North Melbourne
North Shore Private Hospital, St Leonards
Westmead Hospital, Westmead
Cliniques universitaires Saint-Luc (CUSL), Brussels, Brussels
UZ GENT, Ghent
Centre Hospital de l'Ardenne, Libramont
Comprehensive Cancer Center, Plovdiv
UMHAT Sv. Ivan Rilski, Sofia
Institut Bergonie, Bordeaux
Clinique Victor Hugo, Le Mans
Centre Léon Bérard, Lyon
Centre Antoine Lacassagne, Nice
Institut Mutualiste Montsouris, Paris
Centre Hospitalier Quimper, Quimper
CHP Saint Grégoire, Saint-Grégoire
Hia Begin, Saint-Mandé
Hopital Foch, Suresnes
LTD High Tech Hosp Medcenter, Batumi
First University Clinic TSMU, Tbilisi
LTD Consilium Medulla, Tbilisi
Ltd Gidmedi, Tbilisi
LtD L.M.National Urology Center, Tbilisi
LTD MMT Hospital, Tbilisi
LTD Todua Clinic, Tbilisi
Onc. Scient. Research Center, Tbilisi
Przychodnia Lekarska KOMED, Konin
Pratia McM Kraków, Krakow
Europejskie Centrum Zdrowia Otwock, Szpital im. Fryderyka Chopina, Otwock
Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., Oddział Chemioterapii, Warsaw
Pan American Center for Oncology Trials, LLC, Rio Piedras
H U Germans Tries i Pujol, Barcelona
Hospital Clínic de Barcelona, Barcelona
Hospital del Mar, Barcelona
Hospital Sant Pau, Barcelona
Institut Català d'Oncologia Hospitalet_ICO Hospitalet, Barcelona
Vall d' Hebron Institute of Oncology (VHIO), Barcelona
Hospital 12 de octubre, Madrid
Hospital Universitario Virgen del Rocio, Seville
FIVO: Instituto Valenciano de Oncología, Valencia
Churchill Hospital, Headington
Charing Cross Hospital, London
Royal Marsden Hospital, Sutton
Musgrove Park Hospital, Taunton
Lead Sponsor
MacroGenics
INDUSTRY